Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1668 results
February 2023
-
Media ReleaseSandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDASubmission supported by comprehensive analytical and clinical data packageDenosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2Sandoz continues to…
-
Story Patient Perspectives
When you think of the word ‘cancer,’ what are the first words that spring to mind? -
Media ReleasePatients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week…
-
Key ReleaseNovartis continues to grow with further core margin expansion and achieves important innovation milestonesAd hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
-
Key ReleaseNovartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovationAnnonce événementielle au sens de l’art. 53 RCExercice entier Chiffre d’affaires net en hausse de +4% (tcc1, -2% USD) et résultat opérationnel core croissant de +8% (tcc, 0% USD) Innovative…
-
Key ReleaseNovartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteineAd-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative Medicines (IM)…
-
Featured NewsNovartis 2022 Financial Results
January 2023
-
Media ReleaseSandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilarSandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar…
-
StatementNovartis provides update on Phase III STAND trial assessing crizanlizumab
-
Media ReleaseSandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolioSandoz plans to acquire worldwide product rights for Mycamine®(micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly…
-
Featured NewsWorld Economic Forum 2023 -
Pulse UpdateNovartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023